PE20091258A1 - Derivados de piridina como activadores de la guanilato ciclasa soluble - Google Patents

Derivados de piridina como activadores de la guanilato ciclasa soluble

Info

Publication number
PE20091258A1
PE20091258A1 PE2008002003A PE2008002003A PE20091258A1 PE 20091258 A1 PE20091258 A1 PE 20091258A1 PE 2008002003 A PE2008002003 A PE 2008002003A PE 2008002003 A PE2008002003 A PE 2008002003A PE 20091258 A1 PE20091258 A1 PE 20091258A1
Authority
PE
Peru
Prior art keywords
halo
pyridine derivatives
pyridin
phenyl
methyl
Prior art date
Application number
PE2008002003A
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Francoise Jeanne Gellibert
Olivier Mirguet
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0723629A external-priority patent/GB0723629D0/en
Priority claimed from GB0813714A external-priority patent/GB0813714D0/en
Priority claimed from GB0816960A external-priority patent/GB0816960D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20091258A1 publication Critical patent/PE20091258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIDINA DE FORMULA (I), DONDE R1 Y R2 SON H, HALO, CF3, ALQUILO C1-C4, ALILO; Y ES FENILO, PIPERIDINA, ENTRE OTROS; R4 ES H O METILO; Z ES (CH2)2, OCH2 O ESTA AUSENTE; A, J Y L SON CH O N; R5 ES H, CH3, ALCOXI C1-C4, ENTRE OTROS; R6 ES H O CH3; X ES (a); R8 ES H O HALO; R9 ES H, HALO, OCF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 1-[6-(2-(4-(4-CIANOFENOXI)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ACIDO 1-[6-(2-(2-METIL-4-(4-TRIFLUOROMETOXIFENIL)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE LA GUANILATO CICLASA SOLUBLE (sGC) Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES CARDIOVASCULARES TALES COMO HIPERTENSION ARTERIAL, ATEROESCLEROSIS, ANGINA DE PECHO, ENTRE OTROS
PE2008002003A 2007-12-03 2008-12-01 Derivados de piridina como activadores de la guanilato ciclasa soluble PE20091258A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723629A GB0723629D0 (en) 2007-12-03 2007-12-03 Compounds
GB0813714A GB0813714D0 (en) 2008-07-25 2008-07-25 Compounds
GB0816960A GB0816960D0 (en) 2008-09-16 2008-09-16 Compounds

Publications (1)

Publication Number Publication Date
PE20091258A1 true PE20091258A1 (es) 2009-09-12

Family

ID=40717321

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002003A PE20091258A1 (es) 2007-12-03 2008-12-01 Derivados de piridina como activadores de la guanilato ciclasa soluble

Country Status (5)

Country Link
AR (1) AR069517A1 (es)
PE (1) PE20091258A1 (es)
TW (1) TW200938529A (es)
UY (1) UY31507A1 (es)
WO (1) WO2009071504A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032249A1 (en) 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
US8410277B2 (en) 2007-12-26 2013-04-02 Eisai R&D Managment Co., Ltd. Method for manufacturing heterocycle substituted pyridine derivatives
JP5432890B2 (ja) 2008-04-04 2014-03-05 武田薬品工業株式会社 複素環誘導体及びその用途
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
ES2548394T3 (es) * 2010-02-05 2015-10-16 Adverio Pharma Gmbh Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
ME02207B (me) 2010-05-26 2016-02-20 Adverio Pharma Gmbh UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
US20130158028A1 (en) 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
EP2840076B1 (en) 2012-04-16 2017-10-25 TOA Eiyo Ltd. Bicyclic compound
GEP20176631B (en) * 2012-09-07 2017-02-27 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
US20160214956A1 (en) 2013-09-05 2016-07-28 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
KR20160070751A (ko) 2013-10-15 2016-06-20 도아 에이요 가부시키가이샤 4-아미노메틸안식향산 유도체
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
TW201625586A (zh) 2014-07-02 2016-07-16 諾華公司 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625601A (zh) 2014-07-02 2016-07-16 諾華公司 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
ES2784477T3 (es) 2014-07-22 2020-09-28 Boehringer Ingelheim Int Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
CN105980373A (zh) * 2014-09-05 2016-09-28 葛兰素史密斯克莱知识产权发展有限公司 新的可溶性鸟苷酸环化酶活化剂及它们的用途
SG11201701915TA (en) * 2014-09-19 2017-04-27 Glaxosmithkline Ip Dev Ltd Novel soluble guanylate cyclase activators and their use
MX2017014057A (es) 2015-05-06 2018-04-10 Bayer Pharma AG El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de ulceras digitales (du) concomitante con esclerosis sistemica (ssc).
HUE052337T2 (hu) 2015-07-23 2021-04-28 Bayer Pharma AG Oldható guanilát-cikláz stimulátorai/aktivátorai a neutrális endopeptidáz egy inhibitorával (NEP-inhibitor) és/vagy egy angiotenzin All-antagonistával kombinációban és ezek alkalmazása
WO2017103888A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
WO2018069148A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
WO2019211081A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
TW202015676A (zh) 2018-05-15 2020-05-01 德商拜耳廠股份有限公司 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase

Also Published As

Publication number Publication date
AR069517A1 (es) 2010-01-27
UY31507A1 (es) 2009-07-17
TW200938529A (en) 2009-09-16
WO2009071504A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
PE20091258A1 (es) Derivados de piridina como activadores de la guanilato ciclasa soluble
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20091491A1 (es) Compuestos novedosos que son inhibidores de erk
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20051170A1 (es) DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20142099A1 (es) Derivados de sulfonamida
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20080453A1 (es) Derivados de fenil.oxi-fenil-pirimidinona en el tratamiento de malaria
PE20071027A1 (es) Derivados de acido dicarboxilico como activadores de la guanilatociclasa
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20110566A1 (es) Inhibidores ciclicos de 11beta-hidroxiesteroide deshidrogenasa 1
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20060079A1 (es) DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5
PE20130039A1 (es) Pirazoles fungicidas
PE20090972A1 (es) Inhibidores de quinasa c-fms
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal